Extract from an article in SeekingAlpha dated 18 May 2021-...

Extract from an article in SeekingAlpha dated 18 May 2021-
Despite its NASDAQ listing, Immutep has flown under the radar for some time with limited Wall Street coverage, yet if the clinical data continues to strengthen in combination with KEYTRUDA, avelumab, and/or chemotherapy, its 'overlooked & underfollowed' status will not last as the company is well positioned for one or more large biobucks deals or an outright acquisition. This thesis is backed by one of Immutep's largest shareholders, Australian Ethical, a $5 billion fund. In a recent March 2021 article in the Financial Review, Mike Murray, the head of domestic equities for Australian Ethical, said he was most excited about Immutep's trials combining immunotherapy drugs, such as the one with Merck. "There's an unmet need and they have the ability, if you can replicate the data they've seen so far, to have an impact in the space...There's several companies exploring LAG-3... Even if one of the other active companies in this space gets an interesting signal, that's a good thing for Immutep and there might be global interest in these assets," he said. The article then noted, "Mr Murray was confident the company could be an acquisition target for one of the big global biotech companies in the future, thanks to its relationships with the likes of Merck".
As per the last bullet on the right 'news flow' side of the slide above, there are "potential new partnerships and expansion of existing programs" that may occur in 2021. Given its control of efti worldwide ex-China, there would seem to be numerous players, including Merck, Pfizer, Merck KGaA, Novartis, GSK, Bristol Myers, Roche, and others that may have an interest in licensing or acquiring this immune activator for its potential in oncology, autoimmune disease, infectious disease and beyond (these other areas ex-oncology will be covered in a follow up article on Immutep).
This article was written by

Overlooked and UnderfollowedFollow
709 Followers